Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The page’s site “Revision” indicator was updated from v3.5.2 to v3.5.3.
    Difference
    0.1%
    Check dated 2026-04-24T06:12:21.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Revision upgraded from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T02:25:48.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0; no substantive study information changes are evident.
    Difference
    0.1%
    Check dated 2026-03-18T22:28:15.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T19:01:47.000Z thumbnail image
  7. Check
    92 days ago
    Change Detected
    Summary
    Added Primary peritoneal carcinoma as a study condition and added the Genetic and Rare Diseases Information Center as a resource. Removed the government funding lapse notice and updated the page revision to v3.4.2.
    Difference
    0.6%
    Check dated 2026-02-11T04:14:02.000Z thumbnail image
  8. Check
    99 days ago
    Change Detected
    Summary
    A site-wide notice regarding government funding and NIH Clinical Center operations was added. The page revision tag was updated to v3.4.1, replacing v3.4.0.
    Difference
    0.4%
    Check dated 2026-02-04T05:15:49.000Z thumbnail image

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.